1887

Chapter 3 : Perspectives for Developing New Tuberculosis Vaccines Derived from the Pathogenesis of Tuberculosis

Authors: Arthur M. Dannenberg1, Bappaditya Dey6
VIEW AFFILIATIONS HIDE AFFILIATIONS
Affiliations: 1: Department of Environmental Health Sciences; 2: Department of Molecular Microbiology and Immunology; 3: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205; 4: Department of Pathology; 5: Center for Tuberculosis Research, Johns Hopkins School of Medicine, Baltimore, MD 21231; 6: Center for Tuberculosis Research, Johns Hopkins School of Medicine, Baltimore, MD 21231; 7: Howard Hughes Medical Institute, Chevy Chase, MD 20815
Content Type: Monograph
Publication Year: 2017

Category: Bacterial Pathogenesis; Clinical Microbiology

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Preview Magnify
Zoom in
Zoomout

Perspectives for Developing New Tuberculosis Vaccines Derived from the Pathogenesis of Tuberculosis, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819866/9781555819859_Chap03-1.gif /docserver/preview/fulltext/10.1128/9781555819866/9781555819859_Chap03-2.gif

Abstract:

The perspectives described in this chapter address both preclinical tuberculosis (TB) in animal hosts and clinical TB in human populations. They are a guide to how new TB vaccines can be more effectively evaluated in each group. This chapter is not a review of new TB vaccines or the mechanisms in which they may reduce the prevalence or morbidity of TB in the world.

Citation: Dannenberg A, Dey B. 2017. Perspectives for Developing New Tuberculosis Vaccines Derived from the Pathogenesis of Tuberculosis, p 33-44. In Schlossberg D (ed), Tuberculosis and Nontuberculous Mycobacterial Infections, Seventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819866.ch3
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555819866.chap3
1. Dannenberg AM Jr,, Burstone MS,, Walter PC,, Kinsley JW . 1963. A histochemical study of phagocytic and enzymatic functions of rabbit mononuclear and polymorphonuclear exudate cells and alveolar macrophages. I. Survey and quantitation of enzymes, and states of cellular activation. J Cell Biol 17 : 465– 486.
2. Dannenberg AM Jr . 2003. Macrophage turnover, division and activation within developing, peak and “healed” tuberculous lesions produced in rabbits by BCG. Tuberculosis (Edinburgh) 83 : 251– 260.
3. Lurie MB . 1964. Resistance to Tuberculosis: Experimental Studies in Native and Acquired Defensive Mechanisms. Harvard University Press, Cambridge, MA.
4. Dannenberg AM Jr . 1993. Immunopathogenesis of pulmonary tuberculosis. Hosp Pract (Off Ed) 28 : 51– 58.
5. Courtade ET,, Tsuda T,, Thomas CR,, Dannenberg AM . 1975. Capillary density in developing and healing tuberculous lesions produced by BCG in rabbits. A quantitative study. Am J Pathol 78 : 243– 260.
6. Dannenberg AM Jr . 2006. Pathogenesis of Human Tuberculosis: Insights from the Rabbit Model. ASM Press, Washington, DC.
7. Shigenaga T,, Dannenberg AM Jr,, Lowrie DB,, Said W,, Urist MJ,, Abbey H,, Schofield BH,, Mounts P,, Sugisaki K . 2001. Immune responses in tuberculosis: antibodies and CD4-CD8 lymphocytes with vascular adhesion molecules and cytokines (chemokines) cause a rapid antigen-specific cell infiltration at sites of bacillus Calmette-Guérin reinfection. Immunology 102 : 466– 479.
8. Abbas AK,, Lichtman AH . 2009. Basic Immunology: Functions and Disorders of the Immune System, 3rd ed. Saunders/Elsevier, Philadelphia, PA.
9. Dannenberg AM Jr . 2010. Perspectives on clinical and preclinical testing of new tuberculosis vaccines. Clin Microbiol Rev 23 : 781– 794.
10. Dannenberg AM Jr . 1998. Lurie’s tubercle-count method to test TB vaccine efficacy in rabbits. Front Biosci 3 : 27– 33.
11. Dannenberg AM Jr . 1968. Cellular hypersensitivity and cellular immunity in the pathogenesis of tuberculosis: specificity, systemic and local nature, and associated macrophage enzymes. Bacteriol Rev 32 : 85– 102.
12. Ando M . 1973. Macrophage activation in tuberculin reactions of rabbits with primary BCG infection and reinfection. J Reticuloendothel Soc 14 : 132– 145.
13. Rich AR . 1951. The Pathogenesis of Tuberculosis, 2nd ed. Thomas, Springfield, IL.
14. Canetti C . 1955. The Tubercle Bacillus in the Pulmonary Lesion of Man: Histobacteriology and Its Bearing on the Therapy of Pulmonary Tuberculosis. Springer Publishing Co, New York, NY.
15. Dannenberg AM Jr . 2009. Liquefaction and cavity formation in pulmonary TB: a simple method in rabbit skin to test inhibitors. Tuberculosis (Edinburgh) 89 : 243– 247.
16. Menzies D . 1999. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 159 : 15– 21.
17. Thompson NJ,, Glassroth JL,, Snider DE Jr,, Farer LS . 1979. The booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 119 : 587– 597.
18. Cruz A,, Fraga AG,, Fountain JJ,, Rangel-Moreno J,, Torrado E,, Saraiva M,, Pereira DR,, Randall TD,, Pedrosa J,, Cooper AM,, Castro AG . 2010. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis . J Exp Med 207 : 1609– 1616.
19. Tuberculosis Vaccine Candidates . http://www.stoptb.org/wg/new_vaccines/assets/documents/TB%20Vaccine%20Pipeline_rAug%202012.pdf. Accessed 24 September 2012.
20. Seibert FB,, Crumb C,, Dufour EH . 1951. Antigenic differences in two tuberculin protein fractions. J Infect Dis 89 : 252– 258.
21. Kaufmann SH,, Hussey G,, Lambert PH . 2010. New vaccines for tuberculosis. Lancet 375 : 2110– 2119.
22. Raviglione M,, Marais B,, Floyd K,, Lönnroth K,, Getahun H,, Migliori GB,, Harries AD,, Nunn P,, Lienhardt C,, Graham S,, Chakaya J,, Weyer K,, Cole S,, Kaufmann SH,, Zumla A . 2012. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 379 : 1902– 1913.
23. Kupferschmidt K . 2011. Infectious disease. Taking a new shot at a TB vaccine. Science 334 : 1488– 1490.
24. Lurie MB,, Heppleston AG,, Abramson S,, Swartz IB . 1950. Evaluation of the method of quantitative airborne infection and its use in the study of the pathogenesis of tuberculosis. Am Rev Tuberc 61 : 765– 797.
25. Dannenberg AM Jr,, Bishai WR,, Parrish N,, Ruiz R,, Johnson W,, Zook BC,, Boles JW,, Pitt LM . 2000. Efficacies of BCG and vole bacillus ( Mycobacterium microti) vaccines in preventing clinically apparent pulmonary tuberculosis in rabbits: a preliminary report. Vaccine 19 : 796– 800.
26. Manabe YC,, Dannenberg AM Jr,, Tyagi SK,, Hatem CL,, Yoder M,, Woolwine SC,, Zook BC,, Pitt ML,, Bishai WR . 2003. Different strains of Mycobacterium tuberculosis cause various spectrums of disease in the rabbit model of tuberculosis. Infect Immun 71 : 6004– 6011.
27. Dorman SE,, Hatem CL,, Tyagi S,, Aird K,, Lopez-Molina J,, Pitt ML,, Zook BC,, Dannenberg AM Jr,, Bishai WR,, Manabe YC . 2004. Susceptibility to tuberculosis: clues from studies with inbred and outbred New Zealand White rabbits. Infect Immun 72 : 1700– 1705.
28. Subbian S,, Tsenova L,, O’Brien P,, Yang G,, Koo MS,, Peixoto B,, Fallows D,, Zeldis JB,, Muller G,, Kaplan G . 2011. Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology. Am J Pathol 179 : 289– 301.
29. Via LE,, Schimel D,, Weiner DM,, Dartois V,, Dayao E,, Cai Y,, Yoon YS,, Dreher MR,, Kastenmayer RJ,, Laymon CM,, Carny JE,, Flynn JL,, Herscovitch P,, Barry CE III . 2012. Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [ 18F]2-fluoro-deoxy- d-glucose positron emission tomography and computed tomography. Antimicrob Agents Chemother 56 : 4391– 4402.
30. Dey B,, Luna B,, Miller-Jaster K,, Foster B,, Bagci U,, Klunk M,, Mollura DJ,, Jain SK,, Bishai WR . 2012. Qualitative and quantitative analysis of inflammation in pulmonary tuberculosis in rabbit using F18-FDG-PET/CT imaging: a multi-parametric approach. Molecular Imaging of Infectious Diseases: Current Status and Future Challenges. National Institutes of Health, Bethesda, MD.
31. Luna B,, Kubler A,, Larsson C,, Klunk M,, Jain SK,, Bishai WR . 2012. Cavity development in the rabbit model of tuberculosis is independent of inflammation. Molecular Imaging of Infectious Diseases: Current Status and Future Challenges. National Institutes of Health; Bethesda, MD.
32. Brodin P,, Demangel C,, Cole ST, . 2005. Introduction to functional genomics of the Mycobacterium tuberculosis complex, p 143– 153. In Cole ST,, Eisenach KD,, McMurray DN,, Jacobs WR, Jr (ed), Tuberculosis and the Tubercle Bacillus. ASM Press, Washington, DC.
33. Murry JP,, Pandey AK,, Sassetti CM,, Rubin EJ . 2009. Phthiocerol dimycocerosate transport is required for resisting interferon-gamma-independent immunity. J Infect Dis 200 : 774– 782.
34. Volkman HE,, Pozos TC,, Zheng J,, Davis JM,, Rawls JF,, Ramakrishnan L . 2010. Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science 327 : 466– 469.
35. Russell DG, . 2005. Mycobacterium tuberculosis: the indigestible microbe, p 427– 435. In Cole ST,, Eisenach KD,, McMurray DN,, Jacobs WR, Jr (ed), Tuberculosis and the Tubercle Bacillus. ASM Press, Washington, DC.
36. Converse PJ,, Karakousis PC,, Klinkenberg LG,, Kesavan AK,, Ly LH,, Allen SS,, Grosset JH,, Jain SK,, Lamichhane G,, Manabe YC,, McMurray DN,, Nuermberger EL,, Bishai WR . 2009. Role of the dosR-dosS two-component regulatory system in Mycobacterium tuberculosis virulence in three animal models. Infect Immun 77 : 1230– 1237.
37. Jain SK,, Hernandez-Abanto SM,, Cheng QJ,, Singh P,, Ly LH,, Klinkenberg LG,, Morrison NE,, Converse PJ,, Nuermberger E,, Grosset J,, McMurray DN,, Karakousis PC,, Lamichhane G,, Bishai WR . 2007. Accelerated detection of Mycobacterium tuberculosis genes essential for bacterial survival in guinea pigs, compared with mice. J Infect Dis 195 : 1634– 1642.
38. Converse PJ,, Dannenberg AM Jr,, Estep JE,, Sugisaki K,, Abe Y,, Schofield BH,, Pitt ML . 1996. Cavitary tuberculosis produced in rabbits by aerosolized virulent tubercle bacilli. Infect Immun 64 : 4776– 4787.
39. Converse PJ,, Dannenberg AM Jr,, Shigenaga T,, McMurray DN,, Phalen SW,, Stanford JL,, Rook GA,, Koru-Sengul T,, Abbey H,, Estep JE,, Pitt ML . 1998. Pulmonary bovine-type tuberculosis in rabbits: bacillary virulence, inhaled dose effects, tuberculin sensitivity, and Mycobacterium vaccae immunotherapy. Clin Diagn Lab Immunol 5 : 871– 881.
40. Smith PG,, Moss AR, . 1994. Epidemiology of tuberculosis, p 47– 59. In Bloom BR (ed), Tuberculosis: Pathogenesis, Protection, and Control. ASM Press, Washington, DC.
41. Bloom BR,, Fine PEM, . 1994. The BCG experience: implications for future vaccines for tuberculosis, p 531– 557. In Bloom BR (ed), Tuberculosis: Pathogenesis, Protection, and Control. ASM Press, Washington, DC.
42. Aronson JD . 1957. The status of BCG vaccination in the United States and Canada. Bibl Tuberc 13 : 131– 153.
43. Aronson JD,, Aronson CF,, Taylor HC . 1958. A twenty-year appraisal of BCG vaccination in the control of tuberculosis. AMA Arch Intern Med 101 : 881– 893.
44. Medical Research Council . 1972. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Bull World Health Organ 46 : 371– 385.
45. Rosenthal SR,, Loewinsohne E,, Graham ML,, Liveright D,, Thorne G,, Johnson V . 1961. BCG vaccination against tuberculosis in Chicago. A twenty-year study statistically analyzed. Pediatrics 28 : 622– 641.
46. Aronson NE,, Santosham M,, Comstock GW,, Howard RS,, Moulton LH,, Rhoades ER,, Harrison LH . 2004. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study. JAMA 291 : 2086– 2091.
47. Crampin AC,, Glynn JR,, Fine PE . 2009. What has Karonga taught us? Tuberculosis studied over three decades. Int J Tuberc Lung Dis 13 : 153– 164.
48. Barnes PF,, Bloch AB,, Davidson PT,, Snider DE Jr . 1991. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 324 : 1644– 1650.
49. Zevallos K , , et al . 2006. Human cell-mediated immunity against Mycobacterium tuberculosis antigens is augmented by treating intestinal helminths. Am J Trop Med Hyg 75 : 313.
50. Elias D,, Wolday D,, Akuffo H,, Petros B,, Bronner U,, Britton S . 2001. Effect of deworming on human T cell responses to mycobacterial antigens in helminth-exposed individuals before and after bacille Calmette-Guérin (BCG) vaccination. Clin Exp Immunol 123 : 219– 225.
51. Cegielski JP,, McMurray DN . 2004. The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals. Int J Tuberc Lung Dis 8 : 286– 298.
52. Liu PT,, Stenger S,, Tang DH,, Modlin RL . 2007. Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol 179 : 2060– 2063.
53. Colditz GA,, Brewer TF,, Berkey CS,, Wilson ME,, Burdick E,, Fineberg HV,, Mosteller F . 1994. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271 : 698– 702.
54. Comstock GW . 1994. Field trials of tuberculosis vaccines: how could we have done them better? Control Clin Trials 15 : 247– 276.
55. Fine PEM, . 2000. BCG vaccines and vaccination, p 503– 522. In Reichmann LR,, Hershfield ES (ed), Tuberculosis: A Comprehensive International Approach. Marcel Dekker, Inc, New York, NY.
56. Comstock GW,, Woolpert SF . 1978. Tuberculin conversions: true or false? Am Rev Respir Dis 118 : 215– 217.
57. Tuberculosis Research Centre (ICMR) . 1999. Chennai. Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention. Indian J Med Res 110 : 56– 69.

Tables

Perspectives for Developing New Tuberculosis Vaccines Derived from the Pathogenesis of Tuberculosis
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555819866.chap3-1,webId=/content/author/10.1128/9781555819866.chap3-1,properties={foaf_givenname=Arthur M., foaf_name=Arthur M. Dannenberg, foaf_surname=Dannenberg, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555819866.chap3-aff1]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555819866.chap3-2,webId=/content/author/10.1128/9781555819866.chap3-2,properties={foaf_givenname=Bappaditya, foaf_name=Bappaditya Dey, foaf_surname=Dey, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555819866.chap3-aff6]]}]]
Citation: Dannenberg A, Dey B. 2017. Perspectives for Developing New Tuberculosis Vaccines Derived from the Pathogenesis of Tuberculosis, p 33-44. In Schlossberg D (ed), Tuberculosis and Nontuberculous Mycobacterial Infections, Seventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819866.ch3
/content/10.1128/9781555819866.chap3.tab3-1
Table 1

Protective efficacy, DTH response, and CMI response induced by current TB vaccines in preclinical and in clinical trials

Generic image for table
Table 1

Protective efficacy, DTH response, and CMI response induced by current TB vaccines in preclinical and in clinical trials

Citation: Dannenberg A, Dey B. 2017. Perspectives for Developing New Tuberculosis Vaccines Derived from the Pathogenesis of Tuberculosis, p 33-44. In Schlossberg D (ed), Tuberculosis and Nontuberculous Mycobacterial Infections, Seventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819866.ch3

Back to top
This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error